Dr Reddy’s Laboratories (DRL) is expected to face considerable earnings pressure in the first quarter of the current fiscal ended June 30, 2026.The company will announce its first quarter numbers on July 22, 2026.Analysts foresee a possibility of about 35 per cent decline in EBITDA and about 40 per cent dip in the net profit on account of continued pricing pressure in the US market, among others including lack of revenue push from the generic Revlimid and erosion in the base portfolio in the North American market.The drug-maker’s consolidated net profit increased marginally by 1 per cent at ₹1,409 crore in the first quarter that ended June 30, 2025, compared to ₹1,392 crore in the year-ago period on account of price erosion in North America.The revenue, however, increased 11 per cent from ₹7,672 crore in Q1 FY25 to ₹8,545 crore in Q1 FY26.Published on July 21, 2026